Evidence map›Paper›PMID 36192808›Full record

ArticleJournal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale2022

Pathologic complete response following low-dose radiation for advanced oral cavity cancer in a patient with human immunodeficiency virus.

Amy B Leming, Andrea L Johnston, Greg A Krempl, Evan J Fowle, Daniel J Morton, Christina E Henson

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Amy B Leming *College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Andrea L Johnston *Department of Radiation Oncology, University of Oklahoma Health Sciences Center, 800 NE 10th Street, L100, Oklahoma City, OK, 73104, USA.
Greg A KremplDepartment of Otorhinolaryngology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Evan J FowleDepartment of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Daniel J MortonStephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Christina E HensonDepartment of Radiation Oncology, University of Oklahoma Health Sciences Center, 800 NE 10th Street, L100, Oklahoma City, OK, 73104, USA. Christina-henson@ouhsc.edu.ORCID http://orcid.org/0000-0002-5419-4125
University of Oklahoma Health Sciences Center · US

Funding

Tissue Pathology Shared ResourceP30CA225520 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Wade Williams · 2018 to 2026
$27.1M
NCI NIH HHS P30 CA225520NCI NIH HHS P30CA225520
6 · The paper itself

Abstract

backgroundAdvanced squamous cell carcinoma (SCCa) of the oral cavity is often not amenable to curative-intent therapy due to tumor location, tumor size, or comorbidities. CASE PRESENTATION: A 51-year-old male patient with human immunodeficiency virus and on highly active antiretroviral therapy (HAART) presented with a cT4aN2c SCCa of the tongue. He received a preoperative single course of Quad-Shot radiation therapy to 14 Gy in 4 fractions followed by surgical resection. Patient had no residual carcinoma on surgical pathology and no evidence of disease on subsequent clinical and radiological exams.

conclusionsTo our knowledge, this is the first case of pathologic complete response for a patient on HAART following a single cycle of the Quad-Shot regimen for advanced oral cavity SCCa. Protease inhibitors in HAART can induce spontaneous tumor regression via inhibition of proteasome function and activation of apoptosis, and thus act as a cancer therapeutic.

Indexed as

Carcinoma, Squamous CellHIV InfectionsMouth NeoplasmsCombined Modality TherapyHIVHumansMaleMiddle AgedProtease InhibitorsProteasome Endopeptidase ComplexProtease InhibitorsProteasome Endopeptidase ComplexHAARTHIVOral cavity cancerRadiation therapy

Identifiers

PMID36192808
PMCPMC9531370
OpenAlexW4300817661

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.